Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H20N4O9P.Na.2H2O |
Molecular Weight | 514.3562 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.[Na+].CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)COP(O)([O-])=O)C3=NC(=O)NC(=O)C3=N2
InChI
InChIKey=LQVGUKOCMOKKJU-QPVGXXQTSA-M
InChI=1S/C17H21N4O9P.Na.2H2O/c1-7-3-9-10(4-8(7)2)21(15-13(18-9)16(25)20-17(26)19-15)5-11(22)14(24)12(23)6-30-31(27,28)29;;;/h3-4,11-12,14,22-24H,5-6H2,1-2H3,(H,20,25,26)(H2,27,28,29);;2*1H2/q;+1;;/p-1/t11-,12+,14-;;;/m0.../s1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C17H21N4O9P |
Molecular Weight | 456.3438 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including http://rupharma.com/cytoflavin/ and https://ods.od.nih.gov/factsheets/Riboflavin-HealthProfessional/
Curator's Comment: Description was created based on several sources, including http://rupharma.com/cytoflavin/ and https://ods.od.nih.gov/factsheets/Riboflavin-HealthProfessional/
Flavin mononucleotide, or riboflavin-5′-phosphate, is a biomolecule produced from riboflavin by the enzyme riboflavin kinase and functions as prosthetic group of various oxidoreductases including NADH dehydrogenase as well as cofactor in biological blue-light photo receptors. Riboflavin (Vitamin B 2) (as riboflavin 5-phosphate sodium) is an ingredient of the FDA approved composition Infuvite Adult, indicated as a daily multivitamin maintenance supplement for adults and children aged 11 and older receiving parenteral nutrition. Infuvite Adult is also indicated in other situations where administration by the intravenous route is required. Such situations include surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states, which may provoke a “stress” situation with profound alterations in the body’s metabolic demands and consequent tissue depletion of nutrients. Flavin mononucleotide is also a component of Cytoflavin, used for the treatment of consequences of cerebral infarction, for the treatment of atherosclerosis, encephalopathy, neurasthenia. Cytoflavin is marketed in Russian Federation.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7452254
Curator's Comment: Penetrant in rabbits
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Thymidylate synthase-dihydrofolate reductase, Cryptosporidium hominis Sources: http://www.ncbi.nlm.nih.gov/pubmed/19059777 |
55.0 µM [IC50] | ||
Target ID: GO:0006116 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26721206 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Infuvite Adult Approved UseInfuvite Adult is indicated for the prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition Launch Date2003 |
|||
Sources: http://rupharma.com/cytoflavin/ |
Primary | Cytoflavin Approved UseIndicated for the treatment of consequences of cerebral infarction, for the treatment of atherosclerosis, encephalopathy, neurasthenia |
||
Sources: http://rupharma.com/cytoflavin/ |
Primary | Cytoflavin Approved UseIndicated for the treatment of consequences of cerebral infarction, for the treatment of atherosclerosis, encephalopathy, neurasthenia |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1209.4 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
11.6 mg single, intravenous dose: 11.6 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
206.7 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
308.2 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
217.7 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
532.1 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
11.6 mg single, intravenous dose: 11.6 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
886.4 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
981.6 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
883.9 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
PubMed
Title | Date | PubMed |
---|---|---|
Nutritional status and physical working capacity. | 1982 |
|
Urinary riboflavin excretion and erythrocyte glutathione reductase activity in preschool children suffering from upper respiratory infections and measles. | 1987 |
|
Vitamin concentrations in very low birth weight infants given vitamins intravenously in a lipid emulsion: measurement of vitamins A, D, and E and riboflavin. | 1988 Dec |
|
Bioavailability of riboflavin from fortified palm juice. | 1989 Dec |
|
Urinary riboflavin excretion after a load test in rural China as a measure of possible riboflavin deficiency. | 1990 Mar |
|
Folic acid, riboflavin, thiamine, and vitamin B-6 status of a group of first-time blood donors. | 1998 Nov |
|
Riboflavin levels in maternal milk: the influence of vitamin B2 status during the third trimester of pregnancy. | 1999 Aug |
|
Elevation of serum riboflavin carrier protein in breast cancer. | 1999 Nov |
|
Predictors of micronutrient status among six- to twelve-month-old breast-fed Ghanaian infants. | 2000 Feb |
|
Longitudinal vitamin and homocysteine levels in normal pregnancy. | 2001 Jan |
|
Anti-oxidant vitamins and steroid responsive nephrotic syndrome in Indian children. | 2002 Oct |
|
[Nested case-control study on riboflavin levels in blood and urine and the risk of lung cancer]. | 2003 Nov |
|
Involvement of riboflavin kinase expression in cellular sensitivity against cisplatin. | 2011 Apr |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/infuvite-adult.html
Curator's Comment: Can also be taken orally in Cytoflavin formulation http://vitamedd.com/en/pages/1342999
The starting dose of Infuvite Adult is one 10 mL daily dose that is prepared by transferring the content of vial 1 into the content of vial 2 to provide 10 single doses. One 10 mL dose is then added directly to the intravenous fluid. Patients with multiple vitamin deficiencies or with increased vitamin requirements may need multiple daily dosages as indicated.
Each 5 mL of Vial 1* contains 3.6 mg of Riboflavin (Vitamin B 2) (as riboflavin 5-phosphate sodium)
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/19059777
Flavin mononucleotide inhibited Cryptosporidium hominis TS-DHFR with IC50 55 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:13:11 GMT 2023
by
admin
on
Sat Dec 16 14:13:11 GMT 2023
|
Record UNII |
20RD1DZH99
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
812721
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
||
|
NCI_THESAURUS |
C26017
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1201794
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY | |||
|
6184-17-4
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY | |||
|
20RD1DZH99
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY | |||
|
DBSALT000877
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY | |||
|
2611697
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY | |||
|
20RD1DZH99
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY | |||
|
SUB23539
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY | |||
|
100000089013
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY | |||
|
SUB04238MIG
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY | |||
|
1535700
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY | |||
|
23687712
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY | |||
|
C48016
Created by
admin on Sat Dec 16 14:13:12 GMT 2023 , Edited by admin on Sat Dec 16 14:13:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|